Suppr超能文献

比索洛尔在健康志愿者以及肾脏或肝脏疾病患者重复口服给药期间的药代动力学。

Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.

作者信息

Kirch W, Rose I, Demers H G, Leopold G, Pabst J, Ohnhaus E E

出版信息

Clin Pharmacokinet. 1987 Aug;13(2):110-7. doi: 10.2165/00003088-198713020-00003.

Abstract

The pharmacokinetics of bisoprolol were investigated following oral administration of 10mg once daily for 7 days in 8 healthy subjects, in 14 patients with different degrees of renal impairment and in 18 patients with liver disease. In healthy subjects peak and trough steady-state concentrations of 52 micrograms/L and 11 micrograms/L, respectively, an elimination half-life of 10.0 hours and total body clearance of 14.2 L/h were observed. 5.21 mg/24 hours of unchanged bisoprolol were recovered following urinary excretion during the dosage interval. In 11 patients with renal impairment (mean CLCR = 28 +/- 5 ml/min/1.72m2) half-life was prolonged to 18.5 hours, and peak and trough concentrations were 74 and 32 micrograms/L, respectively. Correspondingly, urinary excretion decreased to 3.35 mg/24 hours and total body clearance to 7.8 L/h. In uraemic patients (CLCR less than 5 ml/min/1.73m2) the total clearance of bisoprolol was 5.0 L/h and the elimination half-life was 24.2 hours. In patients with liver cirrhosis half-life increased to 13.5 hours, steady-state peak and trough concentrations increased to 62 and 22 micrograms/L, respectively, and total body clearance decreased to 10.8 L/h. The present study indicates that in patients with impairment of kidney or liver function accumulation of bisoprolol above a factor of 2 did not occur. However, in the terminal stages of insufficiency of kidney or liver function bisoprolol dosage should not exceed 10mg.

摘要

在8名健康受试者、14名不同程度肾功能损害患者和18名肝病患者中,每日口服一次10mg比索洛尔,连续7天,研究了其药代动力学。在健康受试者中,观察到稳态峰浓度和谷浓度分别为52微克/升和11微克/升,消除半衰期为10.0小时,全身清除率为14.2升/小时。在给药间隔期间,经尿液排泄回收的未变化比索洛尔为5.21mg/24小时。在11名肾功能损害患者(平均肌酐清除率=28±5ml/min/1.72m²)中,半衰期延长至18.5小时,峰浓度和谷浓度分别为74和32微克/升。相应地,尿液排泄降至3.35mg/24小时,全身清除率降至7.8升/小时。在尿毒症患者(肌酐清除率小于5ml/min/1.73m²)中,比索洛尔的总清除率为5.0升/小时,消除半衰期为24.2小时。在肝硬化患者中,半衰期增至13.5小时,稳态峰浓度和谷浓度分别增至62和22微克/升,全身清除率降至10.8升/小时。本研究表明,在肾功能或肝功能损害患者中,比索洛尔未出现超过2倍的蓄积。然而,在肾功能或肝功能不全的终末期,比索洛尔剂量不应超过10mg。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验